title: Mesangiolytic glomerulopathy after radiotherapy and chemotherapy of gastric lymphoma.
abstract: Mesangiolytic glomerulopathy is an uncommon complication of irradiation and chemotherapy of THP-COP [pirarubicin, cyclophosphamide (CPA), vincristin (VCR), predonisolone (PSL)] and CHOP (CPA, Doxorubicin, VCR, PSL). We report a case of 63-year-old man 7 months status post radiation, and 10 months post chemotherapy for gastric lymphoma. The patient showed proteinuria and mild renal insufficiency. Renal biopsy revealed marked mesangiolysis in the glomeruli without any immune depositions. After the administration of angiotensin II receptor blocker, the patient's renal function remained stable for over two years. Mesangiolysis was thought to be a characteristic glomerular lesion in this patient treated with both chemoagents and radiation.
authors.affiliation: Division of Nephrology, Kurume University School of Medicine. ymjunko@med.kurume-u.ac.jp
authors.forename: Junko
authors.initials: J
authors.lastname: Yoshimura
authors.forename: Seiya
authors.initials: S
authors.lastname: Kato
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Tamaki
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kohno
authors.forename: Utako
authors.initials: U
authors.lastname: Kaneyuki
authors.forename: Mitsuhide
authors.initials: M
authors.lastname: Maeda
authors.forename: Yuiko
authors.initials: Y
authors.lastname: Saikusa-Itoh
authors.forename: Ayako
authors.initials: A
authors.lastname: Hayashida
authors.forename: Shuji
authors.initials: S
authors.lastname: Iida
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Suefuji
authors.forename: Seiya
authors.initials: S
authors.lastname: Okuda
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D019808:Losartan; D011241:Prednisone